General Toxicity Notes
Most agents in this group are malabsorbed in the presence of compounds that contain metals such as magnesium, calcium, aluminum, and iron. Poorly absorbed with antacids, sucralfate, and phosphate binders.
Half-Life (Normalesrd) Hours
12-15/14.5-16
Plasma Protein Binding %
45-50
Volume Of Distribution L/Kg
1.7-3.5
Dose For Normal Renal Function
400 mg q24h
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: No data, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: No data, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: 400 mg q24h, [B]
References
Burkhardt O, Borner K, Stass H, Beyer G, Allewelt M, Nord CE, et al. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. Scand J Infect Dis. 2002; 34: 898-903. [PMID: 12587622] / Fuhrmann V, Schenk P, Jaeger W, Ahmed S, Thalhammer F. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. J Antimicrob Chemother. 2004; 54: 780-4. [PMID: 15347636] / Ittner KP, Roth G, Gruber M, Pawlik M, Taeger K. Clearance of moxifloxacin during continuous haemofiltration (CVVHF) in vitro. J Antimicrob Chemother. 2005; 56: 360-4. [PMID: 15983025] / Stass H, Kubitza D, Halabi A, Delesen H. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol. 2002; 53: 232-7. [PMID: 11874385]